CD8A and neoplasm: In a mouse breast cancer model, blockade of the RANK/RANKL signal increased CD8+ T cells and reduced other types of immunosuppressive TILs such as TAMs and neutrophils, leading to enhancement of anti-tumor immunotherapies in breast cancer [58].